Oncology

4/1334 → 9/976; +0.62 percentage points of formation share.

What almost every one of these nine companies is chasing is not a new drug so much as a new targeting mechanism, a way to make an existing therapeutic modality show up only where the tumor is and behave differently everywhere else. SynsoryBio's proteins that "sense where they are in the body," Eugit Therapeutics' tissue-specific delivery, and Granza Bio's programmable immune particles are all variations on the same wager: that the ceiling on cancer treatment is precision, not potency. That's a real departure from the older idea of oncology as finding the most powerful cytotoxic agent, and it shows up even in the vaccine and cell-therapy players, since Adventris is going after KRAS specifically because broad immunogenicity has failed so often, and Modulari-T is building synthetic gene switches rather than a single fixed therapy. The timing tracks with the maturing of programmable and AI-guided protein design tools since around 2022, which made it practical for small startups, rather than only large pharma, to engineer conditional activation and explainable targeting platforms like Serinus Biosciences claims. What's striking is the gap between this formation's 3.08x growth and the 0.45x rate of the broader "Cancer Therapeutics" and "Therapeutics" formations it sits inside, suggesting founders and capital are concentrating specifically in precision-delivery oncology while the rest of therapeutics broadly cools. That divergence implies investors increasingly treat "another cancer drug" and "a new way to aim a cancer drug" as fundamentally different bets, with the latter absorbing a disproportionate share of new formation activity.

No comparable outside activity is connected yet.